As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting articles from the emerging economic regions and publications on COVID-19 and CML.

Read Professor Hughes' CML publications of the month: December 2022

Clinical papers

• Management of TKI-resistant chronic phase CML - Review
  Hughes TP and Shanmunagathan N. Hematology Am Soc Hematol Educ Program,
  December 2022
• Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic-phase: the ASC4FIRST phase III trial
  Cortes JE et al. Future Oncol, December 2022 (epub ahead of print) - open access publication
• Treatment of CML in pregnancy
  Robertson HF and Apperley JF. Hematology Am Soc Hematol Educ Program, December 2022
• Measurable residual disease in leukemia - Review
  Branford S and Apperley JF. Haematologica, December 2022 – open access publication
• De novo lymphoid blast phase chronic myeloid leukemia: report and contemporary discussion
  Hameed M et al. Hematology, December 2022 – open access publication
• Current management of chronic myeloid leukemia myeloid blast crisis - Review
  Yohanan B and George B. Clin Med Insights Oncol, December 2022 (epub ahead of print)
• A practical guide to managing hypertension, hyperlipidemia, and hyperglycemia in patients with chronic myeloid leukemia - Review
  Ahmed K et al. Front Med (Lausanne), December 2022 – open access publication
  
• A review of the therapeutic role of the new third-generation TKI Olverembatinib in chronic myeloid leukemia - Review
  Qian H et al. Front Oncol, December 2022 - open access publication
• Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
  Ono T et al. Int J Hematol, December 2022 – open access publication
• Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
  Ureshino H et al. Hematology, December 2022 – open access publication
• Transplantation in CML in the TKI era: who, when, and how?
  Niederwieser C and Kröger N. Hematology Am Soc Hematol Edu Program, December 2022

Scientific papers

• Genetic landscape of chronic myeloid leukemia - Review
  Ochi Y. Int J Hematol, December 2022 (epub ahead of print)
• Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition
  Bütow M et al. Haematologica, December 2022 (epub ahead of print) – open access publication
  
• Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
  Karg E et al. Front Oncol, December 2022 – open access publication

Pediatric CML papers

• Recent progress in the management of pediatric chronic myeloid leukemia – Review
  Shima H and Shimada H. Int J Hematol, December 2022 (epub ahead of print)
• Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  Nishiyama-Fujita Y et al. Ann Med, December 2022 – open access publication
• Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia
  Schleicher O et al. Front Oncol. September 2022 – open access publication

ERSAP papers

• Assessment of molecular response to tyrosine kinase inhibitors in Tunisian patients with chronic myeloid leukemia
  Frikha R et al. J Oncol Pharm Pract, December 2022 - open access publication

COVID-19 papers

• COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
  Milojkovic D et al. Leukemia, December 2022 (epub ahead of print) – open access publication
  
• COVID-19 and blood cancer in the vaccination era
  Hicks LK and Vijenthira A. Blood, December 2022